Human menstrual blood-derived stem cells reverse sorafenib resistance in hepatocellular carcinoma cells through the hyperactivation of mitophagy

Abstract Background Sorafenib is a first-line drug targeting the RTK-MAPK signalling pathway used to treat advanced hepatocellular carcinoma (HCC). However, tumour cells readily develop sorafenib resistance, limiting long-term therapy with this drug. In our previous study, we found that human menstr...

Полное описание

Библиографические подробности

Главные авторы:	Sining Zhou, Yiming Liu, Qi Zhang, Huikang Xu, Yangxin Fang, Xin Chen, Jiamin Fu, Yin Yuan, Yifei Li, Li Yuan, Charlie Xiang
Формат:	Artigo
Язык:	Inglês
Опубликовано:	BMC 2023-04-01
Серии:	Stem Cell Research & Therapy
Предметы:	Hepatocellular carcinoma Sorafenib resistance MenSCs Combination therapy
Online-ссылка:	https://doi.org/10.1186/s13287-023-03278-8
Метки:	Добавить метку Нет меток, Требуется 1-ая метка записи!